Arcutis Biotherapeutics vs Zai Lab
ARQT and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARQT and ZLAB compare
Zai Lab is the larger company, worth 11 times as much as Arcutis Biotherapeutics ($36.5B against $3.4B).
Arcutis Biotherapeutics grew revenue faster over the last twelve months (76.1% versus 5.1% for Zai Lab).
Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 6.1% compared with −41.9% at Zai Lab.
Arcutis Biotherapeutics scores higher on the StockData Score (11 against 7 for Zai Lab), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARQT | ZLAB |
|---|---|---|
| Size and price | ||
| Market cap | $3.4B | $36.5B |
| Share price | $27.15 | $23.47 |
| Change, 1 year | 18.8% | 8.0% |
| Change, 5 years | 62.9% | −69.5% |
| Beta (5Y) | 1.17 | 1.46 |
| Employees | 354 | 1,784 |
| StockData Score | ||
| Total score | 11 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 3 | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 123× | – |
| P/S | 7.4× (better) | 81.1× |
| P/B | 15.5× (better) | 60.0× |
| EV/EBITDA | 95.8× | – |
| P/FCF | 87.2× | – |
| FCF yield | 1.1% (better) | −0.38% |
| Fair value | $5.46 | $4.52 |
| Margin of safety | −397% (better) | −420% |
| Growth | ||
| Revenue growth (TTM) | 76.1% (better) | 5.1% |
| Revenue growth, 5Y average | – | 56.5% |
| Profitability | ||
| Gross margin | 91.1% (better) | 56.5% |
| Operating margin | 7.4% (better) | −58.7% |
| Net margin | 6.1% (better) | −41.9% |
| FCF margin | 8.4% (better) | −31.0% |
| Return on equity | 15.9% (better) | −26.9% |
| Return on invested capital | 36.9% (better) | −90.4% |
| Financial health | ||
| Debt / equity | 0.49 | 0.39 (better) |
| Net debt / EBITDA | −3.79 | – |
| Interest coverage | 2.5× (better) | −44.1× |
| Current ratio | 2.92 (better) | 2.13 |
| Altman Z-score | 6.33 | 43.35 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 2.8% |
| Held by insiders | 9.3% | 0.67% |
| Insider net buying, 12 months | −$11.1M | −$10.7M (better) |
| Short interest, % of float | 15.9% | – |
Go deeper
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
- ZLAB stock overview
- ZLAB income statement
- ZLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.